Y-Type Sets
Y-type designs allow controlled access to blood and compatible fluid lines and are widely used in operating rooms and emergency departments.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Y-type, Straight, Other), By Application (Surgery & Trauma, Chronic Disease Management, Oncology Treatments, Others), By End User (Hospitals, Blood Banks & Centers, Ambulatory Surgical Centers), By Product Quality Tier (Premium / Regulated Markets, Standard / Developed Markets, Economy / Developing Markets), By Distribution Channel (Direct Sales to Large Institutions, Medical Supplies Distributors, Tenders & Government Contracts), and Regional Forecast, 2026-2034
The global blood transfusion market was valued at USD 83.4 million in 2025 and is estimated at USD 86.2 million in 2026. The market is projected to reach USD 112.8 million by 2034, representing a 3.4% CAGR during 2026–2034.
The blood transfusion market covered here is centered on sterile transfusion administration sets used to deliver whole blood or blood components such as red cells, platelets and plasma to patients. The product category includes Y-type, straight and other transfusion sets with tubing, filters, clamps and connectors designed to support safe intravenous administration.
Underlying clinical demand remains broad and recurring. WHO reported 120.4 million blood donations globally in its 2026 blood-safety update, with major differences in donation rates and component-processing capacity across income groups. Transfusion remains critical in surgery, trauma, oncology, chronic anemia, obstetric hemorrhage and hematologic disease, sustaining demand for reliable single-use administration sets.
Regulatory and standards requirements remain central to supplier competitiveness. FDA classifies blood transfusion sets under the intravascular administration-set regulation as Class II devices and recognizes ISO 1135-4:2025 for single-use gravity transfusion sets. This places design quality, filtration, connector integrity, sterility and flow performance at the center of product development and procurement.
Source: WHO blood safety; WHO 2025 global status report; FDA blood transfusion set classification; AABB transfusion guideline.
The study defines the global blood transfusion market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Y-type; Straight; Other |
| By Application | Surgery & Trauma; Chronic Disease Management; Oncology Treatments; Others |
| By End User | Hospitals; Blood Banks & Centers; Ambulatory Surgical Centers |
| By Product Quality Tier | Premium / Regulated Markets; Standard / Developed Markets; Economy / Developing Markets |
| By Distribution Channel | Direct Sales to Large Institutions; Medical Supplies Distributors; Tenders & Government Contracts |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; France; United Kingdom; Italy; China; Japan; South Korea; India; Brazil; Mexico; Saudi Arabia; UAE and other relevant markets |
| Key Market Players | B. Braun; Terumo; Grifols; Fresenius Kabi; GAMA Group; Welford Manufacturing; Helm Medical; Vogt Medical; JMS Co.; Wego; Suzhou Laishi |
The market includes sterile single-use blood transfusion sets and closely related administration-set products used to transfer whole blood or blood components from a blood container to the patient. Revenue covers Y-type, straight and other set configurations with integrated filters, tubing and connectors.
Blood bags, apheresis systems, blood-processing instruments, transfusion diagnostics, blood components and plasma-derived medicinal products are outside the core revenue boundary unless discussed as demand drivers for transfusion-set utilization.
WHO reports 120.4 million blood donations in the latest global data set. Every transfusion event requires safe administration hardware, linking market volume directly to surgical, trauma and chronic-care demand.
Major surgery, emergency trauma and obstetric hemorrhage require rapid access to blood components and reliable administration sets. The non-elective nature of these cases supports stable hospital purchasing even when healthcare budgets tighten.
AABB guidelines recommend restrictive red-cell transfusion thresholds for most stable hospitalized adults. Better patient blood management can reduce unnecessary transfusions, making market growth more dependent on procedure volumes and access expansion than on liberal transfusion practice.
Transfusion sets must maintain sterile fluid pathways, appropriate filtration and dependable flow. Failures can directly affect patient safety, so hospitals and blood centers place significant weight on regulatory compliance and supplier quality systems.
WHO reports large differences in blood donation rates and component-processing capacity between high- and low-income countries. Investments in national blood systems and hospital infrastructure can expand the addressable transfusion-set market.
Source: WHO blood safety; AABB guideline; FDA blood set classification.
Hospitals in developed markets increasingly prioritize products aligned with recognized standards, reliable filtration and safer connector performance. This supports premium positioning for established manufacturers.
Restrictive transfusion strategies and patient blood management reduce avoidable transfusion while preserving essential use in high-risk populations. Suppliers therefore benefit most from safe, efficient products rather than from indiscriminate volume growth.
WHO reported that 133 of 168 responding countries had a national blood policy in the latest data set, while 120 had legislation covering transfusion safety and quality. Stronger governance supports formal procurement and product-quality requirements.
WHO data show lower rates of component separation in lower-income countries than in high-income markets. As blood-processing capability improves, demand can shift toward more standardized component administration and transfusion hardware.
FDA currently recognizes the seventh edition of ISO 1135-4, published in 2025, for single-use gravity transfusion sets. Standards updates reinforce ongoing supplier investment in design control and testing.
Source: WHO report; FDA BRZ classification; FDA microfilter classification.
Blood transfusion sets are mature devices, but product value still depends on tubing design, filtration, connectors, flow control and compatibility with clinical workflows.
Y-type designs allow controlled access to blood and compatible fluid lines and are widely used in operating rooms and emergency departments.
Straight sets provide a simpler fluid pathway for routine transfusion and can offer lower cost and easier setup in standardized workflows.
Filters help remove clots or aggregates and are a critical safety component of transfusion-set design.
Modern sets use standardized connectors, clamps and line-management features to reduce handling complexity and support safer administration.
Source: FDA blood set classification; FDA microfilter classification.
By type, the market is segmented into Y-type, straight and other transfusion sets. Y-type sets are the leading segment because they provide greater workflow flexibility during emergency, surgical and high-acuity transfusion.
Y-type sets allow blood and compatible IV fluid pathways to be managed through a branching configuration, making them highly useful when rapid switching or concurrent fluid support is needed.
Straight sets provide a direct blood-administration pathway and are used where simpler transfusion protocols and cost efficiency are prioritized.
Other designs include specialty pediatric, filtered and procedure-specific configurations adapted to institutional preferences or particular clinical uses.
Y-type sets are expected to retain the largest value share, while straight and specialty configurations remain important in cost-sensitive and procedure-specific settings.
By application, the market is segmented into surgery and trauma, chronic disease management, oncology treatments and other uses. Surgery and trauma remain the leading application because acute blood loss often requires immediate transfusion.
Operating rooms, emergency departments and trauma centers require rapid blood administration during major blood loss, creating the largest and most time-critical demand segment.
Patients with severe anemia, thalassemia, sickle cell disease and other hematologic conditions may require repeated transfusion over long periods.
Cancer patients can require red-cell or platelet transfusion because of chemotherapy-associated marrow suppression, bleeding or hematologic malignancy.
Other applications include obstetric hemorrhage, transplant care and selected intensive-care scenarios where component transfusion is medically indicated.
Surgery and trauma will remain the largest application, while chronic hematology and oncology support recurring demand outside acute-care episodes.
By end user, the market is segmented into hospitals, blood banks and centers, and ambulatory surgical centers. Hospitals are the leading end user because most transfusion episodes occur in inpatient, emergency, surgical or oncology settings.
Hospitals use transfusion sets across emergency care, surgery, intensive care, oncology and hematology and therefore account for the largest recurring purchasing volume.
Blood centers support collection, processing and distribution and may also procure administration products for affiliated clinical services or transfusion programs.
ASCs represent a smaller segment but can require transfusion capability for selected high-acuity procedures and emergency preparedness.
Hospitals will remain the dominant end user, while blood centers influence institutional standards and ASCs provide incremental demand as procedure complexity rises.
By product quality tier, the market is segmented into premium regulated, standard developed-market and economy developing-market products. Premium regulated products lead value because safety and compliance are non-negotiable in major hospital systems.
Premium sets are designed to meet stringent recognized standards and are supplied by established manufacturers with comprehensive quality systems and documentation.
Standard products balance regulatory compliance with cost efficiency and compete strongly through institutional contracts and distributor networks.
Economy products serve highly price-sensitive systems but face stronger scrutiny around consistency, regulatory compliance and procurement quality.
Premium and standard regulated products are expected to capture most value growth as procurement systems place greater emphasis on patient safety and documented quality.
By distribution channel, the market is segmented into direct institutional sales, medical supplies distributors, and tenders or government contracts. Direct sales to large institutions lead value in mature markets because hospital groups negotiate standardized procurement agreements.
Large hospitals and health systems purchase directly from major manufacturers to standardize products, pricing and supply across multiple facilities.
Distributors extend coverage to smaller hospitals, clinics and geographically dispersed markets and can bundle transfusion sets with broader infusion portfolios.
Government and national health systems use tender-based procurement to secure large volumes, particularly where transfusion services are centrally organized.
Direct institutional contracts will remain important in developed markets, while tenders and distributor networks drive broader access across public and emerging healthcare systems.
Regional demand follows transfusion volumes, hospital infrastructure and blood-system quality. North America is the largest demand market, while Europe remains the leading production hub and Asia-Pacific provides the strongest long-term expansion opportunity.
North America leads through high surgical intensity, trauma care, oncology treatment and mature transfusion services.
Europe accounts for more than 40% of global transfusion-set production in the market framework and combines strong manufacturing with mature hospital demand.
China, India, Japan and Southeast Asia combine growing hospital infrastructure with large patient populations and improving national blood systems.
Brazil, Mexico and Argentina support growing institutional demand, while product quality and public procurement shape supplier competition.
GCC countries have advanced transfusion systems, while many African markets still face blood shortages and infrastructure limitations that constrain administration-set demand.
Source: WHO blood safety; WHO report.
Transfusion sets are regulated medical devices used in a safety-critical clinical process. Device quality, sterility and compliance operate alongside blood-system governance, donor screening and haemovigilance.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| U.S. Class II classification | FDA classifies blood transfusion sets under 21 CFR 880.5440. | Requires 510(k) review and quality-system compliance for U.S. marketing. |
| ISO 1135-4:2025 recognition | FDA recognizes the current standard for single-use gravity transfusion sets. | Provides detailed expectations for modern transfusion-set design and performance. |
| Blood-system governance | WHO reports 133 of 168 responding countries had a national blood policy. | Supports more standardized procurement and clinical-use frameworks. |
| Haemovigilance | WHO encourages systems for reporting adverse transfusion events and monitoring the full transfusion chain. | Increases focus on safe administration practices and traceable devices. |
Source: FDA BRZ; WHO report.
The market is mature and competitive, with global infusion companies and regional medical-device manufacturers competing through product quality, price, distribution and institutional relationships. Regulatory compliance and dependable supply are especially important because transfusion sets are high-volume single-use devices.
Large device companies leverage broad infusion portfolios, hospital contracts and global regulatory capabilities.
Companies with broader blood-management or infusion portfolios compete through clinical relationships and regional manufacturing scale.
Regional manufacturers compete through price, tailored product configurations and distributor networks.
Source: FDA classification; WHO blood safety.
June 2026: WHO published its Global Status Report on Blood Safety and Availability 2025, based on data from 168 countries and providing updated evidence on blood collection, component processing, governance and haemovigilance.
September 2026 update: FDA’s current blood-transfusion-set classification page lists ISO 1135-4:2025 as a recognized consensus standard for single-use gravity transfusion equipment.
2026: WHO reported 120.4 million blood donations globally and continued to highlight major access gaps between high- and lower-income countries, reinforcing the need for stronger national blood systems and standardized transfusion infrastructure.
Source: WHO global report; FDA BRZ; WHO fact sheet.
The global blood transfusion market market is projected to grow from USD 86.2 million in 2026 to USD 112.8 million by 2034, at a 3.4% CAGR during 2026–2034. Growth is expected to remain steady because transfusion sets are mature single-use devices tied to essential clinical procedures. Expansion will come from higher surgical volumes, stronger blood systems in emerging markets and migration toward more tightly regulated products rather than from major changes in device technology.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Global transfusion need | WHO reports 120.4 million blood donations. | Supports a large recurring administration base. |
| Surgical demand | Trauma and complex surgery remain major transfusion uses. | Maintains non-discretionary hospital demand. |
| Chronic care | Hematology and oncology create repeated transfusion episodes. | Supports recurring set utilization. |
| Standards updates | ISO 1135-4:2025 is recognized by FDA. | Raises the quality benchmark for suppliers. |
| Emerging-market access | Blood availability and component processing remain uneven. | Creates long-term infrastructure-led growth potential. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global blood transfusion market landscape.
24LifeScience develops blood transfusion market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines the defined transfusion-set market structure with current WHO blood-safety evidence, FDA device classification and international transfusion-practice guidance. Market coverage is limited to administration sets rather than the economic value of donated blood or blood components.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 83.4 million in 2025 and is estimated at USD 86.2 million in 2026. It is projected to reach USD 112.8 million by 2034 at a 3.4% CAGR during 2026–2034.
The market covers sterile blood transfusion administration sets, including Y-type, straight and other configurations used to deliver blood or blood components.
Y-type transfusion sets are the leading type because they provide greater flexibility in surgical, emergency and high-acuity clinical workflows.
Surgery and trauma is the largest application because acute blood loss often requires immediate transfusion.
North America is the largest demand market, while Europe is a major global production hub.
WHO reports 120.4 million blood donations in its latest global data set.
FDA recognizes ISO 1135-4:2025 for transfusion equipment for medical use, including single-use gravity transfusion sets.
The report profiles B. Braun, Terumo, Grifols, Fresenius Kabi, GAMA Group, Welford Manufacturing, Helm Medical, Vogt Medical, JMS, Wego and Suzhou Laishi.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.